Opioid use and healthcare costs among patients with DPNP initiating duloxetine versus other treatments

References

• Cole BE. Diabetic peripheral neuropathic pain: recognition and management. Pain Med 2007;8(Suppl 2):S27-32
   PubMed Web of Science ®Google Scholar
• Argoff CE, Cole BE, Fishbain DA, et al. Diabetic peripheral neuropathic pain: clinical and quality-of-life issues. Mayo Clin Proc 2006;81:S3-11
   PubMed Web of Science ®Google Scholar
• Boulton AJ, Malik RA, Arezzo JC, et al. Diabetic somatic neuropathies. Diabetes Care 2004;27:1458-86
   PubMed Web of Science ®Google Scholar
• Boulton AJM. Management of diabetic peripheral neuropathy. Clin Diabet 2005;23:9-15
   Google Scholar
• Boulton AJ, Vinik AI, Arezzo JC, et al. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 2005;28:956-62
   PubMed Web of Science ®Google Scholar
• Galer BS, Gianas A, Jensen MP. Painful diabetic polyneuropathy: epidemiology, pain description, and quality of life. Diabetes Res Clin Pract 2000;47:123-8
   PubMed Web of Science ®Google Scholar
• Gore M, Brandenburg NA, Hoffman DL, et al. Burden of illness in painful diabetic peripheral neuropathy: the patients' perspectives. J Pain 2006;7:892-900
   PubMed Web of Science ®Google Scholar
• Chong MS, Hester J. Diabetic painful neuropathy: current and future treatment options. Drugs 2007;67:569-85
   PubMed Web of Science ®Google Scholar
• Jude EB, Jacob K. Managing painful neuropathy in diabetes. Pol Arch Med Wewn 2008;118:260-1
   PubMedGoogle Scholar
• Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-53
   PubMed Web of Science ®Google Scholar
• Diabetic peripheral neuropathic pain. Consensus guidelines for treatment. J Fam Pract 2006;June (Suppl):3-19
   Google Scholar
• Argoff CE, Backonja MM, Belgrade MJ, et al. Consensus guidelines: treatment planning and options. Diabetic peripheral neuropathic pain. Mayo Clin Proc 2006;81:S12-25
   Google Scholar
• Wu EQ, Birnbaum HG, Mareva MN, et al. Cost-effectiveness of duloxetine versus routine treatment for U.S. patients with diabetic peripheral neuropathic pain. J Pain 2006;7:399-407
   Google Scholar
• Jensen TS, Backonja MM, Hernandez JS, et al. New perspectives on the management of diabetic peripheral neuropathic pain. Diab Vasc Dis Res 2006;3:108-19
   PubMedGoogle Scholar
• Varkonyi T, Kempler P. Diabetic neuropathy: new strategies for treatment. Diabetes Obes Metab 2008;10:99-108
   PubMed Web of Science ®Google Scholar
• Wong MC, Chung JW, Wong TK. Effects of treatments for symptoms of painful diabetic neuropathy: systematic review. BMJ 2007;335:87
   PubMed Web of Science ®Google Scholar
• Zin CS, Nissen LM, Smith MT, et al. An update on the pharmacological management of post-herpetic neuralgia and painful diabetic neuropathy. CNS Drugs 2008;22:417-42
   PubMed Web of Science ®Google Scholar
• Robinson-Papp J, Simpson DM. Safety profile of treatment in diabetic peripheral neuropathic pain. Pain Med 2007;8(Suppl 2):S43-9
   PubMed Web of Science ®Google Scholar
• Benyamin R, Trescot AM, Datta S, et al. Opioid complications and side effects. Pain Physician 2008;11:S105-20
   PubMed Web of Science ®Google Scholar
• Sullivan MD, Edlund MJ, Fan MY, et al. Trends in use of opioids for non-cancer pain conditions 2000-2005 in commercial and Medicaid insurance plans: the TROUP study. Pain 2008;138:440-9
   PubMed Web of Science ®Google Scholar
• Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-19
   PubMed Web of Science ®Google Scholar
• Braden JB, Fan MY, Edlund MJ, et al. Trends in use of opioids by noncancer pain type 2000-2005 among Arkansas Medicaid and HealthCore enrollees: results from the TROUP study. J Pain 2008;9:1026-35
   PubMed Web of Science ®Google Scholar
• Bureau of Labor Statistics: Consumer Price Index. January 2008. 2010
   Google Scholar
• Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983;70:41-55
   Web of Science ®Google Scholar
• Gilson AM, Ryan KM, Joranson DE, et al. A reassessment of trends in the medical use and abuse of opioid analgesics and implications for diversion control: 1997-2002. J Pain Symptom Manage 2004;28:176-88
   PubMed Web of Science ®Google Scholar
• Wu N, Chen S, Boulanger L, et al. Duloxetine compliance and its association with healthcare costs among patients with diabetic peripheral neuropathic pain. J Med Econ 2009;12:192-202
   PubMedGoogle Scholar
• Chaturvedi N. The burden of diabetes and its complications: trends and implications for intervention. Diabetes Res Clin Pract 2007;76(Suppl 1):S3-S12
   PubMed Web of Science ®Google Scholar
• Boulanger L, Zhao Y, Bao Y, et al. A retrospective study on the impact of comorbid depression or anxiety on healthcare resource use and costs among diabetic neuropathy patients. BMC Health Serv Res 2009;9:111
   PubMed Web of Science ®Google Scholar
• Barrett AM, Lucero MA, Le T, et al. Epidemiology, public health burden, and treatment of diabetic peripheral neuropathic pain: a review. Pain Med 2007;8(Suppl 2):S50-62
   PubMed Web of Science ®Google Scholar
• Boulton AJ. Treatment of symptomatic diabetic neuropathy. Diabetes Metab Res Rev 2003;19(Suppl 1):S16-21
   PubMed Web of Science ®Google Scholar
• Cryer B. NSAID gastrointestinal toxicity. Curr Opin Gastroenterol 2000;16:495-502
   PubMed Web of Science ®Google Scholar
• Currie CJ, Poole CD, Woehl A, et al. The financial costs of healthcare treatment for people with type 1 or type 2 diabetes in the UK with particular reference to differing severity of peripheral neuropathy. Diabet Med 2007;24:187-94
   PubMed Web of Science ®Google Scholar